This filing relates to the resale from time to time, by the selling shareholders, of up to an aggregate of 4.35B ordinary shares of Biodexa Pharmaceuticals, represented by 10.87M American Depositary Shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biodexa Pharmaceuticals Secures $5M Funding
- Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
- Biodexa Pharmaceuticals Unveils Series J Warrant
- Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
- Biodexa Pharmaceuticals prices $5M registered direct offering at 94c per share